B. Braun to Pick Up NxStage’s Bloodlines Business

The acquisition is contingent upon the $2 billion merger between Fresenius and NxStage.

Braun Medical is set to acquire NxStage Medical’s bloodlines business. The potential acquisition is subject to Federal Trade Commission approval and is contingent upon the closing of the $2 billion merger between NxStage and Waltham, MA-based Fresenius Medical Holdings.

The bloodlines business is operated under the Medisystems name.

“We are pleased to add the Streamlinebloodline to our dialysis product portfolio,” Sam Amory, Vice President of B. Braun Medical, said in a release. “Although we have been selling Streamline for many years, this acquisition will allow us to more broadly promote Streamline’s benefits as part of our transformative system of products, which includes the Dialog hemodialysis machine and the Diacap PRO dialyzer.”

Fresenius first announced it would make a move to acquire Lawrence, MA -based NxStage in August of 2017.

The acquisition of NxStage is an opportunity to position Fresenius as a global leader in the home dialysis market. NxStage has made a name for itself in the dialysis market with its System One, a portable hemodialysis system designed for patients to use at home, rather than having to go to a dialysis center for treatment.

Filed Under
500 characters remaining